Search results
Results from the WOW.Com Content Network
Allergan, Inc. was an American global pharmaceutical company focused on eye care, neurosciences, medical dermatology, medical aesthetics, breast enhancement, obesity intervention and urologics. Allergan, Inc. was formed in 1948, incorporated in 1950 and became a public company in 1970. [ 2 ]
Allergan plc is an American, Irish-domiciled pharmaceutical company that acquires, develops, manufactures and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology.
Actavis Generics [1] (formerly known as Watson Pharmaceuticals and Actavis plc, prior to the acquisition of Irish-based Allergan, Inc.) is a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products. Actavis has a commercial ...
The company was founded by Hans Lowey in 1956 as a small laboratory service company. [2]In 1967, the company became a public company via an initial public offering. [3]Ten years later, Howard Solomon became the chief executive officer of the company.
He believed selling to Valeant would not create long-term value for Allergan's shareholders due to Valeant's historic reliance on cost-cutting. [28] Pyott is known to value aggressive research and development for Allergan, which he said had enabled Allergan to launch several new products and increase annual sales by an average of 11% since 2011 ...
In August 2004, the company prevailed in a patent case by Teva Pharmaceutical Industries related to Sarafem (). [5] On May 19, 2006, the company received approval from the Food and Drug Administration for Sarafem.
[6] [11] Patients were allowed to take their usual acute treatment of migraine at least two hours after taking ubrogepant. [6] 23% of patients were taking a preventive medication for migraine. [6] In December 2019, the US Food and Drug Administration approved Ubrelvy produced by Allergan USA, Inc. for treatment of migraine after onset. [6] [12]
Under Papa's leadership, by early 2018, the company had become profitable again; had settled the Allergan case for less than expected; and had lowered its debt by $6.5 billion. [ 101 ] [ 102 ] The company had divested itself of 13 non-core businesses, reducing its debt to $25 billion, and had settled or dismissed 70 pending lawsuits, including ...